Yanling Li Email and Phone Number

I am Yanling LI, now working as a new drug R & D manager in Shanghai Biomed-union Biotechnology Co., Ltd., from Sep 2018, mainly engaging in the study of oncolytic adenovirus combined with immune checkpoint inhibitors on cancer. During my PhD study in Huazhong University of Science and Technology from September 2003 to June 2007, I studied mechanisms of learning and memory of hippocampal neuronal networks. After graduation, I continued to do the research of mechanisms of development of hippocampal neuronal networks in National Laboratory for Optoelectronics until March 2008. In April 2008, I went to CNRS in France to do my Post-Doc research of mechanisms of development of spinal cord until July 2010. In October 2010, I worked as an assistant researcher in the Institute of medical and health engineering, Shenzhen Institute of Advance Technology, Chinese Academy of Science. By using electrophysiology, optogenetics, animal behavior, immunohistochemistry, laser confocal imaging, cellular and molecular biology and other methods and techniques, I studied mechanisms and the treatment strategies of neurological diseases which including autism spectrum disorder, epilepsy, neuropathic pain, schizophrenia, etc. At the same time, I studied mechanisms of skillful movement learning and memory. I obtained my own NSFC funding in 2012, studied early development mechanisms of abnormal neural microcircuits in autism spectrum disorders. In July 2013, I worked as an associate researcher in the Institute of neuroscience, Chinese Academy of Science, studied mechanisms of image-background recognition in the primary visual cortex (V1). In February 2014, I worked in Shanghai Institute of Materia Medica, Chinese Academy of Sciences, mainly engaged in new drug research and development of carbohydrate and related compounds for treatment of neurological diseases and cancer. In July 2017, I worked as a new drug R & D manager in Obio Technology (Shanghai) Corp., Ltd mainly engaging in gene therapy drug research and development for neurological diseases and cancer, and also CRO research.